Search | Clinical Trials Finder

Conditions: Obesity
Interventions: CP-945,598 Treatment B, CP-945,598 Treatment A, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 15
States / cities: Peoria, Arizona • Newport Beach, California • Miami, Florida + 12 more

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: Nutrient; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 1 Day to 6 Months
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alzheimer Disease
Interventions: Citicoline supplement, Placebo; Dietary Supplement · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Breast Cancer
Interventions: In-person education, E-communication, Control; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Liver Fibrosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions: Dietary Supplement/Behavioral: Navy Bean-Rich Diet, Habitual Diet (Control); Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Coeliac Disease, Celiac Disease
Interventions: Amlitelimab, Placebo, SIGE, Gluten-free product (GFP); Drug · Dietary Supplement
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 35
States / cities: Scottsdale, Arizona • Arcadia, California • Lancaster, California + 32 more

Conditions: Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Inulin, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration; Procedure · Dietary Supplement · Biological + 1 more
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Dyslipidemia
Interventions: Saturated Fat Diet; Dietary Supplement
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 18 Years to 70 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Bariatric Surgery Candidate, Diet Modification
Interventions: Dietary modification with introduction of Mankai; Other
Lead sponsor: Cleveland Clinic Florida; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Placebo, Metformin (blinded), Metformin (open-label); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: San Diego, California • Baton Rouge, Louisiana • San Antonio, Texas

Conditions: Diabetes, Diabetes Mellitus, Type 1, Type1diabetes, Diabetes Mellitus
Interventions: YG1699, Dapagliflozin; Drug
Lead sponsor: Youngene Therapeutics Inc., Ltd.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type 2 Diabetes
Interventions: Plant-based diet with no oxysterols, Standard ADA Diet (SADA); Behavioral
Lead sponsor: Morehouse School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetes Type 2
Interventions: BMS-770767, Placebo, Metformin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Lomita, California • Las Vegas, Nevada

Conditions: Prostate Cancer
Interventions: Exercise and Diet; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Atopic Dermatitis, Food Allergies
Interventions: B. infantis, Placebo; Drug
Lead sponsor: Emanual Maverakis, MD; Other
Eligibility: 1 Day to 7 Days
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Breast Cancer, Lung Cancer, Prostate Cancer
Interventions: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell), Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo, Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).; Dietary Supplement · Drug
Lead sponsor: Optimal Health Research; Other
Eligibility: 25 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cancer
Interventions: Medically Tailored Grocery Plus Nutrition Counseling Group, Experimental: Medically Tailored Grocery Group, Standard of Care Group with Delayed Medically Tailored Grocery Delivery; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Appetite and General Nutritional Disorders
Interventions: HP-Beverage Breakfast, HP-Solid Breakfast, Breakfast Skipping; Behavioral
Lead sponsor: Purdue University; Other
Eligibility: 20 Years to 32 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Nonarteritic Anterior Ischemic Optic Neuropathy
Interventions: RPh201 Cohort A, Placebo Cohort A, RPh201 Cohort B, Placebo Cohort B; Drug · Other
Lead sponsor: Regenera Pharma Ltd; Industry
Eligibility: 50 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 15
States / cities: Palo Alto, California • Pasadena, California • Orange, Connecticut + 12 more

Conditions: Diabetes Mellitus, Type 2, Diabetic Nephropathy
Interventions: Attention control, Intervention; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Obstetric Labour, Premature
Interventions: GSK221149 750 mg, Ketoconazole, GSK221149 100 mg, GSK221149 750 mg Fasted, GSK221149 750 mg + Food; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Body Weight
Interventions: Control diet, Low Pulse diet, High Pulse diet; Other
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Davis, California

Conditions: Eosinophilic Esophagitis
Interventions: Oral Budesonide, Elimination diet; Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 3 Years to 17 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Breast Cancer, Obesity
Interventions: Fit2ThriveMB App, Fitbit, Physical Activity Coaching Calls, Healthy Living Coaching Calls, Cancer.net app; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.

Genetic Regulation of Surfactant Deficiency

Improving Sleep and Cognition in Alzheimer's Disease

Diet and Physical Activity Changes Among Latina Breast Cancer Survivors

Isocaloric Navy-Bean Substitution in Adults With MASLD

A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

Effect of Saturated Fat on Large Low-density Lipoprotein (LDL) and High-density Lipoprotein (HDL)

Effects of Wolffia Globosa (Mankai) in Patients Undergoing Bariatric Surgery.

A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes

Dietary Oxysterols and β-Cell Function Among African Americans

Safety Study of BMS-770767 in Subjects With Type 2 Diabetes

Diet and Exercise Interventions Among Men With Prostate Cancer (Prostate 8-II)

Probiotic Supplementation in Breastfed Newborn Infants

A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.

Nourishing Hope: The Impact of Nutrition in Cancer Treatment and Recovery in Maine

The Effects of a High Protein Breakfast on Appetite and Sleep in Young Adults

Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Enhancing Adherence in Type 2 Diabetes: The ENHANCE Study

A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole

Pulse Biomarker Discovery

Eosinophilic Esophagitis Clinical Therapy Comparison Trial

Technology-Supported Physical Activity Intervention for Metastatic Breast Cancer Survivors: Fit2ThriveMB